SEARCH

SEARCH BY CITATION

REFERENCES

  • Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D. 2006. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67:17571763.
  • Augustin S, Huebbe P, Matzner N, Augustin K, Schliebs R, Cermak R, Wolffram S, Rimbach G. 2008. Ginkgo biloba extract and its flavonol and terpenelactone fractions do not affect beta-secretase mRNA and enzyme activity levels in cultured neurons and in mice. Plant Med 74:613.
  • Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. 2000. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 12:18821890.
  • Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. 2006. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci 23:5564.
  • Bate C, Tayebi M, Williams A. 2008. Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. Mol Neurodegen 3:1.
  • Baum L, Ng A. 2004. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 6:367377; discussion 443-9.
  • Bayer TA, Schafer S, Simons A, Kemmling A, Kamer T, Tepest R, Eckert A, Schussel K, Eikenberg O, Sturchler-Pierrat C, Abramowski D, Staufenbiel M, Multhaup G. 2003. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci USA 100:1418714192.
  • Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG. 2004. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24:41814186.
  • Bodles AM, El-Agnaf OM, Greer B, Guthrie DJ, Irvine GB. 2004. Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Neurosci Lett 359:8993.
  • Burdick D, Kosmoski J, Knauer MF, Glabe CG. 1997. Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, A beta 1-42, in differentiated PC12 cells. Brain Res 746:275284.
  • Bush AI. 2003. The metallobiology of Alzheimer's disease. Trends Neurosci 26:207214.
  • Caragounis A, Du T, Filiz G, Laughton KM, Volitakis I, Sharples RA, Cherny RA, Masters CL, Drew SC, Hill AF, Li QX, Crouch PJ, Barnham KJ, White AR. 2007. Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands. Biochem J 407:435450.
  • Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. 1997. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem 69:24522465.
  • Castillo GM, Cummings JA, Yang W, Judge ME, Sheardown MJ, Rimvall K, Hansen JB, Snow AD. 1998. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47:612620.
  • Castillo GM, Lukito W, Wight TN, Snow AD. 1999. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 72:16811687.
  • Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665676.
  • Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. 1997. Acceleration of amyloid fibril formation by specific binding of Abeta-(1–40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272:2298722990.
  • Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. 2003. Self-assembly of Abeta(1–42) into globular neurotoxins. Biochemistry 42:1274912760.
  • Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, Cattabeni F, Christen Y, Di Luca M. 2004. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 16:454460.
  • Cruz M, Tusell JM, Grillo-Bosch D, Albericio F, Serratosa J, Rabanal F, Giralt E. 2004. Inhibition of beta-amyloid toxicity by short peptides containing N-methyl amino acids. J Pept Res 63:324328.
  • Di Vaira M, Bazzicalupi C, Orioli P, Messori L, Bruni B, Zatta P. 2004. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem 43:37953797.
  • Diaz-Nido J, Wandosell F, Avila J. 2002. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 23:13231332.
  • Doig AJ, MacArthur MW, Stapley BJ, Thornton JM. 1997. Structures of N-termini of helices in proteins. Protein Sci 6:147155.
  • Doraiswamy PM, Finefrock AE. 2004. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol 3:431434.
  • Dudas B, Cornelli U, Lee JM, Hejna MJ, Walzer M, Lorens SA, Mervis RF, Fareed J, Hanin I. 2002. Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25–35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol Aging 23:97104.
  • Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE. 2000. Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease. Dement Geriatr Cogn Disord 11:181186.
  • Esteras-Chopo A, Pastor MT, Serrano L, Lopez de la Paz M. 2008. New strategy for the generation of specific D-peptide amyloid inhibitors. J Mol Biol 377:13721381.
  • Fenili D, Brown M, Rappaport R, McLaurin J. 2007. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med 85:603611.
  • Fisher AE, Naughton DP. 2005. Why nutraceuticals do not prevent or treat Alzheimer's disease. Nutr J 4:14.
  • Fraser PE, Nguyen JT, Chin DT, Kirschner DA. 1992. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 59:15311540.
  • Fraser PE, Darabie AA, McLaurin JA. 2001. Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides. implications for drug development. J Biol Chem 276:64126419.
  • Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM. 2001. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 22:9931005.
  • Frid P, Anisimov SV, Popovic N. 2007. Congo red and protein aggregation in neurodegenerative diseases. Brain Res Rev 53:135160.
  • Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST. 2000. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology 54:11091116.
  • Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. 2007. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102:10951104.
  • Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, Szarek WA, Tremblay P. 2007. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28:537547.
  • Ghanta J, Shen CL, Kiessling LL, Murphy RM. 1996. A strategy for designing inhibitors of beta-amyloid toxicity. J Biol Chem 271:2952529528.
  • Glabe CC. 2005. Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem 38:167177.
  • Gnjec A, Fonte JA, Atwood C, Martins RN. 2002. Transition metal chelator therapy: a potential treatment for Alzheimer's disease? Front Biosci 7:d1016–d1023.
  • Gordon DJ, Meredith SC. 2003. Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions. Biochemistry 42:475485.
  • Gordon DJ, Sciarretta KL, Meredith SC. 2001. Inhibition of beta-amyloid (40) fibrillogenesis and disassembly of beta-amyloid (40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 40:82378245.
  • Gordon DJ, Tappe R, Meredith SC. 2002. Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis. J Pept Res 60:3755.
  • Gorman PM, Yip CM, Fraser PE, Chakrabartty A. 2003. Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH. J Mol Biol 325:743757.
  • Greenberg SM, Rosand J, Schneider AT, Creed Pettigrew L, Gandy SE, Rovner B, Fitzsimmons BF, Smith EE, Edip Gurol M, Schwab K, Laurin J, Garceau D. 2006. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord 20:269274.
  • Gupta-Bansal R, Frederickson RC, Brunden KR. 1995. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J Biol Chem 270:1866618671.
  • Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353356.
  • Hughes E, Burke RM, Doig AJ. 2000. Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25–35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J Biol Chem 275:2510925115.
  • Hughes SR, Goyal S, Sun JE, Gonzalez-DeWhitt P, Fortes MA, Riedel NG, Sahasrabudhe SR. 1996. Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. Proc Natl Acad Sci USA 93:20652070.
  • Jeon SY, Bae K, Seong YH, Song KS. 2003. Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett 13:39053908.
  • Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. 2002. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41:73857390.
  • Kapurniotu A, Schmauder A, Tenidis K. 2002. Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol 315:339350.
  • Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486489.
  • Kim DS, Park SY, Kim JK. 2001. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1–42) insult. Neurosci Lett 303:5761.
  • Kim H, Park BS, Lee KG, Choi CY, Jang SS, Kim YH, Lee SE. 2005. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 53:85378541.
  • Kim SJ, Jeong HJ, Lee KM, Myung NY, An NH, Yang WM, Park SK, Lee HJ, Hong SH, Kim HM, Um JY. 2007. Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 18:587596.
  • Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. 1995. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1:143148.
  • Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S. 2007. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 14:2132.
  • Klunk WE, Debnath ML, Koros AM, Pettegrew JW. 1998. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci 63:18071814.
  • Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ. 2006. N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 45:99069918.
  • Lane TJ, Sam A, Kandathil AJ. 1960. Chelate stabilities of certain oxine-type compounds. J Am Chem Soc 82:44624464.
  • Leveugle B, Scanameo A, Ding W, Fillit H. 1994. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport 5:13891392.
  • Levites Y, Amit T, Mandel S, Youdim MB. 2003. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (−)-epigallocatechin-3-gallate. Faseb J 17:952954.
  • Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. 2001. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:83708377.
  • Longpre F, Garneau P, Christen Y, Ramassamy C. 2006. Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic Biol Med 41:17811794.
  • Lorenzo A, Yankner BA. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91:1224312247.
  • Lowe TL, Strzelec A, Kiessling LL, Murphy RM. 2001. Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 40:78827889.
  • Manavalan P, Momany FA. 1980. Conformational energy studies on N-methylated analogs of thyrotropin releasing hormone, enkephalin, and luteinizing hormone-releasing hormone. Biopolymers 19:19431973.
  • Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M. 2006. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45:60856094.
  • Mathis CA, Lopresti BJ, Klunk WE. 2007. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 34:809922.
  • Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX. 2002. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 277:4467044676.
  • McLaurin J, Fraser PE. 2000. Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions. Eur J Biochem 267:63536361.
  • McLaurin J, Chakrabartty A. 1996. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem 271:2648226489.
  • McLaurin J, Franklin T, Chakrabartty A, Fraser PE. 1998. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J Mol Biol 278:183194.
  • McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE. 1999. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur J Biochem 266:11011110.
  • McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. 2000. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem 275:1849518502.
  • McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P. 2006. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12:801808.
  • Miyamura Y, Koga T, Higashi N. 2006. Amyloid inhibitors consisting of Ab-binding peptides and poly(ethylene glycol). Polymer Preprints, The Society of Polymer Science, Japan. 55:53045305.
  • Mizuno T, Nakata M, Naiki H, Michikawa M, Wang R, Haass C, Yanagisawa K. 1999. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J Biol Chem 274:1511015114.
  • Necula M, Kayed R, Milton S, Glabe CG. 2007. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282:1031110324.
  • Nitz M, Fenili D, Darabie AA, Wu L, Cousins JE, McLaurin J. 2008. Modulation of amyloid-beta aggregation and toxicity by inosose stereoisomers. FEBS J 275:16631674.
  • Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, Town T, Tan J. 2006. ADAM10 activation is required for green tea (−)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 281:1641916427.
  • Ono K, Hasegawa K, Naiki H, Yamada M. 2004. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75:742750.
  • Oohira A, Matsui F, Tokita Y, Yamauchi S, Aono S. 2000. Molecular interactions of neural chondroitin sulfate proteoglycans in the brain development. Arch Biochem Biophys 374:2434.
  • Pai AS, Rubinstein I, Onyuksel H. 2006. PEGylated phospholipid nanomicelles interact with beta-amyloid((1–42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro. Peptides 27:28582866.
  • Pallitto MM, Ghanta J, Heinzelman P, Kiessling LL, Murphy RM. 1999. Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry 38:35703578.
  • Park SY, Kim DS. 2002. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease. J Nat Prod 65:12271231.
  • Phinney AL, Drisaldi B, Schmidt SD, Lugowski S, Coronado V, Liang Y, Horne P, Yang J, Sekoulidis J, Coomaraswamy J, Chishti MA, Cox DW, Mathews PM, Nixon RA, Carlson GA, St George-Hyslop P, Westaway D. 2003. In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci USA 100:1419314198.
  • Poduslo JF, Curran GL, Kumar A, Frangione B, Soto C. 1999. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 39:371382.
  • Pollack SJ, Sadler, II, Hawtin SR, Tailor VJ, Shearman MS. 1995a. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells. Neurosci Lett 184:113116.
  • Pollack SJ, Sadler, II, Hawtin SR, Tailor VJ, Shearman MS. 1995b. Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Neurosci Lett 197:211214.
  • Porat Y, Abramowitz A, Gazit E. 2006. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67:2737.
  • Raman B, Ban T, Yamaguchi K, Sakai M, Kawai T, Naiki H, Goto Y. 2005. Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid beta peptide. J Biol Chem 280:1615716162.
  • Ramassamy C. 2006. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545:5164.
  • Reinke AA, Gestwicki JE. 2007. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 70:206215.
  • Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J. 2005. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25:88078814.
  • Reznichenko L, Amit T, Zheng H, Avramovich-Tirosh Y, Youdim MB, Weinreb O, Mandel S. 2006. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (−)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 97:527536.
  • Rijkers DT, Hoppener JW, Posthuma G, Lips CJ, Liskamp RM. 2002. Inhibition of amyloid fibril formation of human amylin by N-alkylated amino acid and alpha-hydroxy acid residue containing peptides. Chemistry 8:42854291.
  • Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. 2003. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:16851691.
  • Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:28662875.
  • Sigurdsson EM, Permanne B, Soto C, Wisniewski T, Frangione B. 2000. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol 59:1117.
  • Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wight TN. 1988. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol 133:456463.
  • Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Wight TN. 1990. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Am J Pathol 137:12531270.
  • Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG. 1994. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 12:219234.
  • Soto C, Kindy MS, Baumann M, Frangione B. 1996. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 226:672680.
  • Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. 1998. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4:822826.
  • Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF. 2003. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 184:510520.
  • Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. 2007. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. Faseb J 21:24002408.
  • Terzi E, Holzemann G, Seelig J. 1995. Self-association of beta-amyloid peptide (1–40) in solution and binding to lipid membranes. J Mol Biol 252:633642.
  • Tjernberg A, Edlund PO, Noren B. 1998. Screening of eltanolone metabolites in dog urine by anion-exchange/reversed-phase liquid chromatography and mass spectrometry. J Chromatogr B Biomed Sci Appl 715:395407.
  • Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C. 1996. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271:85458548.
  • Tjernberg LO, Lilliehook C, Callaway DJ, Naslund J, Hahne S, Thyberg J, Terenius L, Nordstedt C. 1997. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem 272:1260112605.
  • Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ. 2006. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60:668676.
  • Treiber C, Simons A, Strauss M, Hafner M, Cappai R, Bayer TA, Multhaup G. 2004. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 279:5195851964.
  • van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. 2003. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2:482492.
  • Vitolo O, Gong B, Cao Z, Ishii H, Jaracz S, Nakanishi K, Arancio O, Dzyuba SV, Lefort R, Shelanski M. 2009. Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkolide. J Neurobiol Aging 30:257265.
  • Walzer M, Lorens S, Hejna M, Fareed J, Hanin I, Cornelli U, Lee JM. 2002. Low molecular weight glycosaminoglycan blockade of beta-amyloid induced neuropathology. Eur J Pharmacol 445:211220.
  • Waschuk SA, Elton EA, Darabie AA, Fraser PE, McLaurin JA. 2001. Cellular membrane composition defines A beta-lipid interactions. J Biol Chem 276:3356133568.
  • Watanabe K, Segawa T, Nakamura K, Kodaka M, Konakahara T, Okuno H. 2001. Identification of the molecular interaction site of amyloid beta peptide by using a fluorescence assay. J Pept Res 58:342346.
  • Watanabe K, Nakamura K, Akikusa S, Okada T, Kodaka M, Konakahara T, Okuno H. 2002. Inhibitors of fibril formation and cytotoxicity of beta-amyloid peptide composed of KLVFF recognition element and flexible hydrophilic disrupting element. Biochem Biophys Res Commun 290:121124.
  • White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL, Cappai R. 1999. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 842:439444.
  • White AR, Barnham KJ, Bush AI. 2006a. Metal homeostasis in Alzheimer's disease. Expert Rev Neurother 6:711722.
  • White AR, Du T, Laughton KM, Volitakis I, Sharples RA., Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL. 2006b. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281:1767017680.
  • Wiesehan K, Stohr J, Nagel-Steger L, van Groen T, Riesner D, Willbold D. 2008. Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide. Protein Eng Des Sel 21:241246.
  • Woods AG, Cribbs DH, Whittemore ER, Cotman CW. 1995. Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25–35) induced neurodegeneration in cultured hippocampal neurons. Brain Res 697:5362.
  • Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y. 2006. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:1310213113.
  • Yamaguchi H, Maat-Schieman ML, van Duinen SG, Prins FA, Neeskens P, Natte R, Roos RA. 2000. Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. J Neuropathol Exp Neurol 59:723732.
  • Yan LM, Tatarek-Nossol M, Velkova A, Kazantzis A, Kapurniotu A. 2006. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc Natl Acad Sci USA 103:20462051.
  • Yanagisawa K, Ihara Y. 1998. GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain. Neurobiol Aging 19(1 Suppl):S65S67.
  • Yanagisawa K, Odaka A, Suzuki N, Ihara Y. 1995. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med 1:10621066.
  • Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. 1998. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 52:691698.
  • Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. 2005. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892-5901.
  • Yang Jr F, Zhang M, Zhou BR, Chen J, Liang Y. 2006. Oleic acid inhibits amyloid formation of the intermediate of alpha-lactalbumin at moderately acidic pH. J Mol Biol 362:821834.
  • Yao Z, Drieu K, Papadopoulos V. 2001. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res 889:181190.
  • Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. 2000. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 173:4044.
  • Zhu H, Yu J, Kindy MS. 2001. Inhibition of amyloidosis using low-molecular-weight heparins. Mol Med 7:517522.